CA2349696A1 - Controlled release formulation for water soluble drugs - Google Patents

Controlled release formulation for water soluble drugs Download PDF

Info

Publication number
CA2349696A1
CA2349696A1 CA002349696A CA2349696A CA2349696A1 CA 2349696 A1 CA2349696 A1 CA 2349696A1 CA 002349696 A CA002349696 A CA 002349696A CA 2349696 A CA2349696 A CA 2349696A CA 2349696 A1 CA2349696 A1 CA 2349696A1
Authority
CA
Canada
Prior art keywords
layer
diltiazem
water soluble
controlled release
once
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002349696A
Other languages
French (fr)
Other versions
CA2349696C (en
Inventor
Chih-Ming Chen
Xiu Xiu Cheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Andrx Pharmaceuticals LLC
Original Assignee
Andrx Pharmaceuticals, Inc.
Chih-Ming Chen
Xiu Xiu Cheng
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrx Pharmaceuticals, Inc., Chih-Ming Chen, Xiu Xiu Cheng filed Critical Andrx Pharmaceuticals, Inc.
Publication of CA2349696A1 publication Critical patent/CA2349696A1/en
Application granted granted Critical
Publication of CA2349696C publication Critical patent/CA2349696C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Abstract

A once-a-day controlled release diltiazem formulation comprises: (a) 20-50 wt.% of enteric polymeric membrane coated pellets comprising a polymer membrane coated core which comprises a biologically inert core which is coat ed with a first layer consisting essentially of diltiazem and polymeric binder; and a second layer which comprises a membrane comprising a pH dependent polymeric material; and (b) 50-80 wt.% of delayed pulse polymeric membrane coated pellets comprising a polymeric membrane coated core comprising a biologically inert core which is coated with a first layer which consists essentially of diltaziem and a polymeric binder and a second layer which comprises a polymeric membrane and a akaline a alkaline earth metal stearate which will substantially maintain its integrity in the varying pH conditions of the gastrointestinal tract but is permeable to diltiazem, and (c) a unit dose containment system.

Claims (18)

1. A once-a-day controlled release formulation of a water soluble drug which comprises:
(a) from 20 to 50% by weight of enteric polymeric membrane coated pellets comprising a polymer membrane coated core which comprises a biologically inert core which is coated with a first layer which consists essentially of a water soluble drug and a binder; and a second layer which comprises a membrane comprising an enteric coating material; and (b) from 50% to 80% by weight of delayed pulse polymeric membrane coated pellets comprising a polymeric membrane coated core which comprises a biologically inert core which is coated with a first layer which consists essentially of a water soluble drug and a binder polymer and a second layer which comprises a polymeric membrane and an alkaline earth metal stearate said second layer being capable of substantially maintaining its integrity in the varying pH conditions of the gastrointestinal tract and being permeable to diltiazem; and (c) a unit dose containment system.
2. A once-a-day controlled release formulation of a water soluble drug as defined in claim 1 which comprises about 40wt% of (a) and about 60wt% of the pellets of (b).
3. A once-a-day controlled release formulation of a water soluble drug as defined in claim 1 wherein the enteric polymeric coating material is selected from the group consisting of shellac, methacrylic acid copolymers, hydroxypropyl methylcellulose phthalate and cellulose acetate phthalate.
4. A once-a-day controlled release formulation of a water soluble drug as defined in claim 1 wherein the enteric polymeric coating material and the second layer on the delayed pulse pellets both contain a plasticizer.
5. A once-a-day controlled release formulation of a water soluble drug as defined in claim 4 wherein the plasticizer is acetyltributyl citrate.
6. A once-a-day controlled release formulation of a water soluble drug as defined in claim 3 wherein the membrane on the enteric coating polymeric material is a methacrylic acid copolymer.
7. A once-a-day controlled release formulation of a water soluble drug as defined in claim 1 wherein the second layer on the delayed pulse polymeric membrane coated pellets comprises a copolymer of acrylic and methacrylic acid esters with a low content of ammonium groups, magnesium stearate and talc.
8. A once-a-day controlled release of a formulation of a water soluble drug as defined in claim 1 which exhibits in O.1N HCl, a release rate profile which is initially a zero order release rate of the water soluble drug that continues for up to about 12-14 hours and thereafter exhibits a sharp increase in the rate of release of said water soluble drug.
9. A delayed pulse bead formulation of a water soluble drug which comprises membrane coated pellets comprising a polymeric membrane coated core which comprises a biologically inert core which is coated with a first layer which consists essentially of a water soluble drug and a polymeric binder polymer and a second layer which comprises a polymeric membrane, an alkaline earth metal stearate and talc said second layer being capable of substantially maintaining its integrity in the varying pH conditions of the gastrointestinal tract and being permeable to said water soluble drug and which resists any substantial release of said water soluble drug for 12 hours in a USP dissolution Type II apparatus at 37°C , 100rpm in hydrochloric acid at pH 1Ø
10. A once-a-day controlled release diltiazem formulation which comprises:
(a) from 20 to 50% by weight of enteric polymeric membrane coated pellets comprising a polymer membrane coated core which comprises a biologically inert core which is coated with a first layer which consists essentially of diltiazem and a binder; and a second layer which comprises a membrane comprising an enteric coating material; and (b) from 50% to 50% by weight of delayed pulse polymeric membrane coated pellets comprising a polymeric membrane coated core which comprises a biologically inert core which is coated with a combined first layer which consists essentially of diltiazem and a binder polymer and a second layer which comprises a polymeric membrane and an alkaline earth metal stearate said second layer being capable of substantially maintaining its integrity in the varying pH conditions of the gastrointestinal tract and being permeable to diltiazem; and (c) a unit dose containment system.
11. A once-a-day controlled release diltiazem formulation as defined in claim 10 which comprises about 40wt% of (a) and about 60wt% of the pellets of (b).
12. A once-a-day controlled release diltiazem formulation as defined in claim 10 wherein the enteric coating polymeric material is selected from the group consisting of shellac, methacrylic acid copolymers, hydroxy propylmethylcellulose phthalate and cellulose acetate phthalate.
13. A once-a-day controlled release diltiazem formulation as defined in claim 10 wherein the enteric coating polymeric material and the second layer on the delayed pulse pellets both contain a plasticizer.
14. A once-a-day controlled release diltiazem formulation as defined in claim 13 wherein the plasticizer is acetyltributyl citrate.
15. A once-a-day controlled release diltiazem formulation as defined in claim 12 wherein the membrane on the enteric coating polymeric material is a methacrylic acid copolymer.
16. A once-a-day controlled release diltiazem formulation as defined in claim 10 wherein the second layer on the delayed pulse polymeric membrane coated pellets comprises a copolymer of acrylic and methacrylic acid esters with a low content of ammonium groups, magnesium stearate and talc.
17. A once-a-day controlled release diltiazem formulation as defined in claim 10 which exhibits in 0.1N HCl, a release rate profile which is initially a zero order release rate of diltiazem that continues for up to about 12-14 hours and thereafter exhibits a sharp increase in the rate of release of diltiazem.
18. A delayed pulse diltiazem bead formulation which comprises membrane coated pellets comprising a polymeric membrane coated core which comprises a biologically inert core which is coated with a first layer which consists essentially of diltiazem and a polymeric binder polymer and a second layer which comprises a polymeric membrane, an alkaline earth metal stearate and talc, said second layer being capable of substantially maintaining its integrity in the varying pH conditions of the gastrointestinal tract and being permeable to diltiazem and which resists any substantial release of diltiazem for 12 hours in a USP dissolution Type II apparatus at 37°C
100rpm in hydrochloric acid at pH 1Ø
CA002349696A 1998-11-06 1999-11-01 Controlled release formulation for water soluble drugs Expired - Lifetime CA2349696C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/187,319 1998-11-06
US09/187,319 US6270805B1 (en) 1998-11-06 1998-11-06 Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
PCT/US1999/025604 WO2000027370A1 (en) 1998-11-06 1999-11-01 Controlled release formulation for water soluble drugs

Publications (2)

Publication Number Publication Date
CA2349696A1 true CA2349696A1 (en) 2000-05-18
CA2349696C CA2349696C (en) 2010-03-09

Family

ID=22688495

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002349696A Expired - Lifetime CA2349696C (en) 1998-11-06 1999-11-01 Controlled release formulation for water soluble drugs

Country Status (7)

Country Link
US (1) US6270805B1 (en)
EP (1) EP1124543A4 (en)
JP (1) JP4536929B2 (en)
AU (1) AU755287B2 (en)
CA (1) CA2349696C (en)
NZ (1) NZ511448A (en)
WO (1) WO2000027370A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7771750B2 (en) 1999-02-26 2010-08-10 Andrx Pharmaceuticals, Llc Controlled release oral dosage form

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6733789B1 (en) 1999-01-21 2004-05-11 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
US20040185099A1 (en) * 2000-01-20 2004-09-23 Biovail Laboratories, Inc. Multiparticulate bisoprolol formulation
US6544555B2 (en) 2000-02-24 2003-04-08 Advancis Pharmaceutical Corp. Antibiotic product, use and formulation thereof
US6984402B2 (en) 2000-10-03 2006-01-10 Elite Laboratories, Inc. Chrono delivery formulations and method of treating atrial fibrillation
US6620439B1 (en) * 2000-10-03 2003-09-16 Atul M. Mehta Chrono delivery formulations and method of use thereof
US20020068078A1 (en) 2000-10-13 2002-06-06 Rudnic Edward M. Antifungal product, use and formulation thereof
US6790459B1 (en) * 2000-11-03 2004-09-14 Andrx Labs, Llc Methods for treating diabetes via administration of controlled release metformin
US20060034922A1 (en) * 2000-11-03 2006-02-16 Andrx Labs, Llc Controlled release metformin compositions
US6866866B1 (en) * 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
CA2685214C (en) * 2001-02-08 2013-01-22 Andrx Pharmaceuticals, Inc. Improved controlled release oral dosage form
US6837696B2 (en) * 2001-09-28 2005-01-04 Mcneil-Ppc, Inc. Apparatus for manufacturing dosage forms
US7838026B2 (en) 2001-09-28 2010-11-23 Mcneil-Ppc, Inc. Burst-release polymer composition and dosage forms comprising the same
ATE404179T1 (en) 2001-09-28 2008-08-15 Mcneil Ppc Inc DOSAGE FORMS WITH CORE AND OUTER SHELL
US20040253312A1 (en) * 2001-09-28 2004-12-16 Sowden Harry S. Immediate release dosage form comprising shell having openings therein
US7122143B2 (en) 2001-09-28 2006-10-17 Mcneil-Ppc, Inc. Methods for manufacturing dosage forms
US20040146559A1 (en) * 2002-09-28 2004-07-29 Sowden Harry S. Dosage forms having an inner core and outer shell with different shapes
US20030228368A1 (en) * 2001-09-28 2003-12-11 David Wynn Edible solid composition and dosage form
US20030118652A1 (en) * 2001-11-15 2003-06-26 John Kelly Methods and compositions for use of (S)-bisoprolol
US20030091633A1 (en) * 2001-11-15 2003-05-15 John Kelly Methods and compositions for use of (S)-bisoprolol
US20050182056A9 (en) * 2002-02-21 2005-08-18 Seth Pawan Modified release formulations of at least one form of tramadol
US8128957B1 (en) 2002-02-21 2012-03-06 Valeant International (Barbados) Srl Modified release compositions of at least one form of tramadol
US7022342B2 (en) * 2002-03-28 2006-04-04 Andrx Corporation, Inc. Controlled release oral dosage form of beta-adrenergic blocking agents
WO2003099214A2 (en) * 2002-05-23 2003-12-04 Andrx Corporation Biguanide formulations
PA8578501A1 (en) 2002-07-25 2005-02-04 Pharmacia Corp DOSAGE FORM ONCE A DAY OF PRAMIPEXOL
DE60335557D1 (en) * 2002-08-15 2011-02-10 Euro Celtique Sa PHARMACEUTICAL COMPOSITIONS CONTAINED AN OPIOIDANAL GETIC
US7807197B2 (en) * 2002-09-28 2010-10-05 Mcneil-Ppc, Inc. Composite dosage forms having an inlaid portion
US6893660B2 (en) * 2002-11-21 2005-05-17 Andrx Pharmaceuticals, Inc. Stable pharmaceutical compositions without a stabilizer
US20040131672A1 (en) * 2003-01-07 2004-07-08 Nilobon Podhipleux Direct compression pharmaceutical composition containing a pharmaceutically active ingredient with poor flowing properties
US20040208932A1 (en) * 2003-04-17 2004-10-21 Ramachandran Thembalath Stabilized paroxetine hydrochloride formulation
JP2006528185A (en) 2003-07-21 2006-12-14 アドバンシス ファーマスーティカル コーポレイション Antibiotic preparations, their use and preparation
US8313776B2 (en) 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
US8313775B2 (en) 2003-07-21 2012-11-20 Shionogi Inc. Antibiotic product, use and formulation thereof
CA2524300C (en) * 2003-08-08 2008-10-28 Biovail Laboratories International Srl Modified-release tablet of bupropion hydrochloride
EP1653925A1 (en) 2003-08-11 2006-05-10 Advancis Pharmaceutical Corporation Robust pellet
JP2007502294A (en) 2003-08-12 2007-02-08 アドバンシス ファーマスーティカル コーポレイション Antibiotic preparations, their use and preparation
CA2535780A1 (en) * 2003-08-29 2005-03-17 Advancis Pharmaceuticals Corporation Antibiotic product, use and formulation thereof
JP2007513869A (en) 2003-09-15 2007-05-31 アドバンシス ファーマスーティカル コーポレイション Antibiotic preparations, their use and preparation
US20050069590A1 (en) * 2003-09-30 2005-03-31 Buehler Gail K. Stable suspensions for medicinal dosages
US20050074514A1 (en) * 2003-10-02 2005-04-07 Anderson Oliver B. Zero cycle molding systems, methods and apparatuses for manufacturing dosage forms
EP2210605B1 (en) * 2003-11-04 2017-03-01 TCD Royalty Sub, LLC Once daily dosage forms of trospium
US20050142203A1 (en) * 2003-12-30 2005-06-30 Grant Heinicke Oral dosage formulations of active pharmaceutical ingredients and methods of preparing the same
US8067029B2 (en) 2004-01-13 2011-11-29 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US7879354B2 (en) * 2004-01-13 2011-02-01 Mcneil-Ppc, Inc. Rapidly disintegrating gelatinous coated tablets
US20050196447A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196446A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196442A1 (en) * 2004-03-05 2005-09-08 Huang Hai Y. Polymeric compositions and dosage forms comprising the same
US20050196448A1 (en) * 2004-03-05 2005-09-08 Hai Yong Huang Polymeric compositions and dosage forms comprising the same
MXPA06011765A (en) * 2004-04-12 2006-12-15 Pfizer Prod Inc Taste-masked drugs in rupturing multiparticulates.
WO2006014427A1 (en) 2004-07-02 2006-02-09 Advancis Pharmaceutical Corporation Tablet for pulsed delivery
PT1789021E (en) 2004-08-13 2011-12-22 Boehringer Ingelheim Int Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof
JP4971159B2 (en) 2004-08-13 2012-07-11 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Sustained release pellet preparation containing pramipexole or a pharmaceutically acceptable salt thereof, its production method and use
US8383159B2 (en) * 2004-10-27 2013-02-26 Mcneil-Ppc, Inc. Dosage forms having a microreliefed surface and methods and apparatus for their production
US20070190133A1 (en) * 2004-10-27 2007-08-16 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20070281022A1 (en) * 2004-10-27 2007-12-06 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060087051A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088593A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088586A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US20060088587A1 (en) * 2004-10-27 2006-04-27 Bunick Frank J Dosage forms having a microreliefed surface and methods and apparatus for their production
US8673352B2 (en) 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
JP5095615B2 (en) * 2005-06-27 2012-12-12 バリアント・インターナショナル・（バルバドス）・ソサイアティーズ・ウィズ・リストリクティッド・ライアビリティ Modified release of bupropion salt
US8778395B2 (en) * 2005-08-11 2014-07-15 Andrx Labs, Llc Diltiazem controlled release formulation and method of manufacture
US20070077300A1 (en) * 2005-09-30 2007-04-05 Wynn David W Oral compositions containing a salivation inducing agent
US8778924B2 (en) 2006-12-04 2014-07-15 Shionogi Inc. Modified release amoxicillin products
US8357394B2 (en) 2005-12-08 2013-01-22 Shionogi Inc. Compositions and methods for improved efficacy of penicillin-type antibiotics
US8299052B2 (en) 2006-05-05 2012-10-30 Shionogi Inc. Pharmaceutical compositions and methods for improved bacterial eradication
US8703191B2 (en) * 2006-07-25 2014-04-22 Intelgenx Corp. Controlled-release pharmaceutical tablets
US7674479B2 (en) * 2006-07-25 2010-03-09 Intelgenx Corp. Sustained-release bupropion and bupropion/mecamylamine tablets
AU2007309281B2 (en) * 2006-10-20 2013-10-31 Johnson & Johnson Consumer Inc. Acetaminophen / ibuprofen combinations
WO2008065504A1 (en) * 2006-11-30 2008-06-05 Pfizer Products Inc. Multiparticulates of spray-coated drug and polymer on a meltable core
US11116728B2 (en) 2006-11-30 2021-09-14 Bend Research, Inc. Multiparticulates of spray-coated drug and polymer on a meltable core
US20080317677A1 (en) * 2007-06-22 2008-12-25 Szymczak Christopher E Laser Marked Dosage Forms
US20080317678A1 (en) * 2007-06-22 2008-12-25 Szymczak Christopher E Laser Marked Dosage Forms
US20090060983A1 (en) * 2007-08-30 2009-03-05 Bunick Frank J Method And Composition For Making An Orally Disintegrating Dosage Form
KR101560176B1 (en) * 2007-10-31 2015-10-14 맥네일-피피씨, 인코포레이티드 Orally disintegrated dosage form
US8357395B2 (en) * 2007-12-21 2013-01-22 Mcneil-Ppc, Inc. Manufacture of tablet
WO2009118756A2 (en) * 2008-03-24 2009-10-01 Lupin Limited Delayed release compositions of duloxetine
US8282957B2 (en) * 2008-06-26 2012-10-09 Mcneil-Ppc, Inc. Coated particles containing pharmaceutically active agents
US8313768B2 (en) 2009-09-24 2012-11-20 Mcneil-Ppc, Inc. Manufacture of tablet having immediate release region and sustained release region
US8807979B2 (en) 2009-09-24 2014-08-19 Mcneil-Ppc, Inc. Machine for the manufacture of dosage forms utilizing radiofrequency energy
US20110070286A1 (en) * 2009-09-24 2011-03-24 Andreas Hugerth Process for the manufacture of nicotine-comprising chewing gum and nicotine-comprising chewing gum manufactured according to said process
US20110318411A1 (en) 2010-06-24 2011-12-29 Luber Joseph R Multi-layered orally disintegrating tablet and the manufacture thereof
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US9233491B2 (en) 2012-05-01 2016-01-12 Johnson & Johnson Consumer Inc. Machine for production of solid dosage forms
US9445971B2 (en) 2012-05-01 2016-09-20 Johnson & Johnson Consumer Inc. Method of manufacturing solid dosage form
US9511028B2 (en) 2012-05-01 2016-12-06 Johnson & Johnson Consumer Inc. Orally disintegrating tablet
JP6150564B2 (en) * 2013-03-08 2017-06-21 杏林製薬株式会社 Orally rapidly disintegrating tablets
MX368159B (en) 2014-01-10 2019-09-20 Johnson & Johnson Consumer Inc Process for making tablet using radiofrequency and lossy coated particles.
US10736905B1 (en) 2016-09-09 2020-08-11 Shahin Fatholahi Nefopam dosage forms and methods of treatment
US10493026B2 (en) 2017-03-20 2019-12-03 Johnson & Johnson Consumer Inc. Process for making tablet using radiofrequency and lossy coated particles
US11446311B2 (en) 2017-09-08 2022-09-20 Shahin Fatholahi Methods for treating pain associated with sickle cell disease
US10736874B1 (en) 2017-09-08 2020-08-11 Shahin Fatholahi Methods for treating pain associated with sickle cell disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4894240A (en) 1983-12-22 1990-01-16 Elan Corporation Plc Controlled absorption diltiazem formulation for once-daily administration
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
JP2558396B2 (en) 1990-06-28 1996-11-27 田辺製薬株式会社 Controlled release formulation
US5286497A (en) 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
US5252337A (en) * 1991-06-25 1993-10-12 Eurand America, Inc. Controlled release calcium channel blocker microcapsules
US5288505A (en) * 1991-06-26 1994-02-22 Galephar P.R., Inc., Ltd. Extended release form of diltiazem
US5229135A (en) * 1991-11-22 1993-07-20 Prographarm Laboratories Sustained release diltiazem formulation
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
US5834024A (en) 1995-01-05 1998-11-10 Fh Faulding & Co. Limited Controlled absorption diltiazem pharmaceutical formulation
US5567441A (en) * 1995-03-24 1996-10-22 Andrx Pharmaceuticals Inc. Diltiazem controlled release formulation
US5830503A (en) * 1996-06-21 1998-11-03 Andrx Pharmaceuticals, Inc. Enteric coated diltiazem once-a-day formulation
US5914134A (en) * 1997-01-27 1999-06-22 Wockhardt Europe Limited Process for the pulsatile delivery of diltiazem HCL and product produced thereby
US5840329A (en) * 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7771750B2 (en) 1999-02-26 2010-08-10 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US8545880B2 (en) 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US8747898B2 (en) 1999-02-26 2014-06-10 Andrx Pharmaceuticals, Llc Controlled release oral dosage form

Also Published As

Publication number Publication date
EP1124543A4 (en) 2004-03-31
AU1518600A (en) 2000-05-29
US6270805B1 (en) 2001-08-07
JP4536929B2 (en) 2010-09-01
AU755287B2 (en) 2002-12-12
CA2349696C (en) 2010-03-09
NZ511448A (en) 2003-06-30
JP2002529401A (en) 2002-09-10
EP1124543A1 (en) 2001-08-22
WO2000027370A1 (en) 2000-05-18

Similar Documents

Publication Publication Date Title
CA2349696A1 (en) Controlled release formulation for water soluble drugs
US5834023A (en) Diltiazem controlled release formulation
US5885616A (en) Sustained release drug delivery system suitable for oral administration
US5472708A (en) Pulsatile particles drug delivery system
JP5463223B2 (en) Multiparticulate modified release composition
NZ591688A (en) Dosage form comprising time-pulsatile release beads
CA2499574A1 (en) Controlled release preparation
WO1995020946A1 (en) Bilayered amoxycillin tablets
US5830503A (en) Enteric coated diltiazem once-a-day formulation
JP2012107048A (en) Timed pulsatile drug delivery system
JP5592902B2 (en) Sustained release composition of therapeutic agent
JP2002525313A5 (en)
KR20050026515A (en) Oral pharmaceutical formulation in the form of a plurality of microcapsules for prolonged release of active principle(s) with low solubility
WO2012091153A3 (en) Orally disintegrating tablet
JPS63230626A (en) Continuous release vehicle
NZ242730A (en) Diltiazem bead with a central core of active agent coated with a polymer coating and use thereof in sustained release pharmaceutical compositions
US6150410A (en) pH independent extended release pharmaceutical formulation
US20010001658A1 (en) Granule modulating hydrogel system
CA2536666A1 (en) Modafinil modified release pharmaceutical compositions
EP1146864A1 (en) Ph independent extended release pharmaceutical formulation
CA2433915A1 (en) Improved controlled release oral dosage form
MX2007008985A (en) Controlled release compositions comprising an antipsychotic agent.
CA2617351A1 (en) Diltiazem controlled release formulation and method of manufacture
EP1686974A1 (en) Extended release dosage forms of bupropion hydrochloride
WO2007128107A1 (en) Modified release tablets comprising tramadol

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20191101